Wells Fargo Initiates Coverage of Globus Medical (GMED) with an Overweight Rating

What: Wells Fargo initiated coverage of Globus Medical (GMED) with an Overweight rating.
Why: The bank cited the company's strong growth prospects and expanding product portfolio.
Signal: This is a positive signal for GMED investors, indicating potential upside.
Target: Wells Fargo set a price target of $**145** for GMED, implying a potential 15% increase from current levels.
Risk: Investors should be aware of the potential risks associated with the medical device industry, including regulatory changes and competition.